ArticlePancreas2009
Proteomic analyses of pancreatic cyst fluids.
Article in Pancreas, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 45 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
45 citing papers in PubMed, 82 citations in OpenAlex.
- Highly Accurate Identification of Cystic Precursor Lesions of Pancreatic Cancer Through Targeted Mass Spectrometry: A Phase IIc Diagnostic Study.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2018Trial
- Mass Spectrometry-Based Comprehensive Analysis of Pancreatic Cyst Fluids.BioMed research international · 2018Trial
- Cystic lesions and their role in pancreatic cancer risk stratification.Translational oncology · 2026Review
- Cyst fluid proteins stratify malignant risk of intraductal papillary mucinous neoplasm of the pancreas.Cancer letters · 2025Article
- Endoscopic ultrasound-guided fine-needle aspiration for pancreatic cystic lesions: a comprehensive review.Journal of medical ultrasonics (2001) · 2024Review
- The next "sweet" spot for pancreatic ductal adenocarcinoma: Glycoprotein for early detection.Mass spectrometry reviews · 2023Review
- Article
- Proteome alterations in pancreatic ductal adenocarcinoma.Cancer letters · 2020Review
- Elevating pancreatic cystic lesion stratification: Current and future pancreatic cancer biomarker(s).Biochimica et biophysica acta. Reviews on cancer · 2020Review
- Omics Approaches in Pancreatic Adenocarcinoma.Cancers · 2019Review
- Differences inJournal of carcinogenesis & mutagenesis · 2018Article
- Quantitative proteomic analysis of pancreatic cyst fluid proteins associated with malignancy in intraductal papillary mucinous neoplasms.Clinical proteomics · 2018Article
- [Cystic pancreatic tumors: diagnostics and new biomarkers].Der Chirurg; Zeitschrift fur alle Gebiete der operativen Medizen · 2017Review
- Global Protease Activity Profiling Provides Differential Diagnosis of Pancreatic Cysts.Clinical cancer research : an official journal of the American Association for Cancer Research · 2017Article
- Proteomics analysis of bodily fluids in pancreatic cancer.Proteomics · 2015Review
- Systematic Review of Pancreatic Cyst Fluid Biomarkers: The Path Forward.Clinical and translational gastroenterology · 2015Article
- Cyst Fluid Glucose is Rapidly Feasible and Accurate in Diagnosing Mucinous Pancreatic Cysts.The American journal of gastroenterology · 2015Article
- Endoscopic ultrasound in the diagnosis of pancreatic intraductal papillary mucinous neoplasms.World journal of gastroenterology · 2014Review
- Article
- Proteomic mucin profiling for the identification of cystic precursors of pancreatic cancer.Journal of the National Cancer Institute · 2014Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors at 2 institutions in 1 country.
Funding
Abstract
objectivesThere are currently no diagnostic indicators that are consistently reliable, obtainable, and conclusive for diagnosing and risk-stratifying pancreatic cysts. Proteomic analyses were performed to explore pancreatic cyst fluids to yield effective diagnostic biomarkers.
methodsWe have prospectively recruited 20 research participants and prepared their pancreatic cyst fluids specifically for proteomic analyses. Proteomic approaches applied were as follows: (1) matrix-assisted laser-desorption-ionization time-of-flight mass spectrometry peptidomics with LC/MS/MS (HPLC-tandem mass spectrometry) protein identification; (2) 2-dimensional gel electrophoresis; (3) GeLC/MS/MS (tryptic digestion of proteins fractionated by sodium dodecyl sulfate-polyacrylamide gel electrophoresis and identified by LC/MS/MS).
resultsSequencing of more than 350 free peptides showed that exopeptidase activities rendered peptidomics of cyst fluids unreliable; protein nicking by proteases in the cyst fluids produced hundreds of protein spots from the major proteins, making 2-dimensional gel proteomics unmanageable; GeLC/MS/MS revealed a panel of potential biomarker proteins that correlated with carcinoembryonic antigen (CEA).
conclusionsTwo homologs of amylase, solubilized molecules of 4 mucins, 4 solubilized CEA-related cell adhesion molecules (CEACAMs), and 4 S100 homologs may be candidate biomarkers to facilitate future pancreatic cyst diagnosis and risk-stratification. This approach required less than 40 microL of cyst fluid per sample, offering the possibility to analyze cysts smaller than 1 cm in diameter.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.